Persistent cerebellar deterioration in a patient with lobar pneumonia under lithium, carbamazepine, and trifluperidol treatment

1999 ◽  
Vol 14 (3) ◽  
pp. 175-176 ◽  
Author(s):  
F Bischof ◽  
A Melms ◽  
M Fetter
Keyword(s):  
Side Effects ◽  
Combination Therapy ◽  
Therapeutic Range ◽  
Schizoaffective Disorder ◽  
Lithium Toxicity ◽  
Lithium Level ◽  
Serum Lithium Level ◽  
Lobar Pneumonia

SummaryWe report on a patient with schizoaffective disorder who was on combination therapy of lithium, carbamazepine, and the neuroleptic trifluperidol. He experienced a lobar pneumonia and developed an acute and persistent cerebellar deterioration which was most likely due to lithium toxicity, while the serum lithium level was within the therapeutic range. The combination of lithium, carbamazepine, and neuroleptics is common, and is generally considered to be safe. The reported case suggests that this regimen might increase the risk of intoxication with potentially disabling side-effects.

scholarly journals Lithium Toxicity

2016 ◽  
Vol 8 (2) ◽  
Author(s):  
Sophie Corriveau MD ◽  
Amanda Gardhouse MD ◽  
Mark Soth MD ◽  
Craig Ainsworth MD
Keyword(s):  
Bipolar Disorder ◽  
Therapeutic Range ◽  
Sinus Bradycardia ◽  
Elevated Serum ◽  
Lithium Toxicity ◽  
Lithium Level ◽  
Serum Lithium Level ◽  
Narrow Therapeutic Range ◽  
Mood Stabilization

Lithium is commonly prescribed for mood stabilization in bipolar disorder. Lithium has a narrow therapeutic range (0.8−1.2 mmol/L), and even chronic users may unexpectedly develop toxic levels. Toxicities manifest in various ways. The authors report the case of a patient who developed sinus bradycardia and asystolic arrest with an elevated serum lithium level.

Side-effects of lithium at lower therapeutic levels: the significance of thirst

1985 ◽  
Vol 15 (2) ◽  
pp. 355-361 ◽  
Author(s):  
J. R. King ◽  
P. R. Aylard ◽  
R. P. Hullin
Keyword(s):  
Side Effects ◽  
Water Absorption ◽  
Clinical Response ◽  
Psychotropic Drugs ◽  
Urine Flow ◽  
Lithium Level ◽  
Serum Lithium Level ◽  
Length Of Treatment ◽  
Low Levels ◽  
Thirst Mechanism

SynopsisThe prevalence of thirst, subjective polyuria and related side-effects was investigated in 87 patients attending a lithium clinic and in a group of 52 controls. Thirst was surprisingly common, occurring in 67% of patients, in spite of the fact that they had been maintained on relatively low levels of lithium, and was due principally to the lithium rather than to other psychotropic drugs. Urine flow and impaired renal water absorption correlated with the serum lithium level and the length of treatment in the patients, despite the fact that few were clinically polyuric. The pattern of the results confirms previous suggestions that lithium may stimulate the thirst mechanism directly as well as via an increased renal resistance to vasopressin. The possible implications in terms of clinical response are discussed.

Renal side effects of lithium: The importance of the serum lithium level

1981 ◽  
Vol 72 (2) ◽  
pp. 203-204 ◽  
Author(s):  
Per Vestergaard ◽  
Klaus Thomsen
Keyword(s):  
Side Effects ◽  
Lithium Level ◽  
Serum Lithium Level

What is the optimal serum lithium level in the long-term treatment of bipolar disorder? A review

2007 ◽  
Vol 40 (06) ◽  
Author(s):  
E Severus ◽  
N Kleindienst ◽  
F Seemüller ◽  
S Frangou ◽  
HJ Möller ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Term Treatment ◽  
Lithium Level ◽  
Serum Lithium Level ◽  
Long Term Treatment

scholarly journals Combination Therapy with Continuous Three-in-One Femoral Nerve Block and Periarticular Multimodal Drug Infiltration after Total Hip Arthroplasty

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Tomonori Tetsunaga ◽  
Tomoko Tetsunaga ◽  
Kazuo Fujiwara ◽  
Hirosuke Endo ◽  
Toshifumi Ozaki
Keyword(s):  
Side Effects ◽  
Pain Relief ◽  
Total Hip Arthroplasty ◽  
Combination Therapy ◽  
Hospital Stay ◽  
Nerve Block ◽  
Hip Arthroplasty ◽  
Femoral Nerve Block ◽  
Femoral Nerve ◽  
Length Of Hospital Stay

Background. Various postoperative pain relief modalities, including continuous femoral nerve block (CFNB), local infiltration analgesia (LIA), and combination therapy, have been reported for total knee arthroplasty. However, no studies have compared CFNB with LIA for total hip arthroplasty (THA). The aim of this study was to compare the efficacy of CFNB versus LIA after THA. Methods. We retrospectively reviewed the postoperative outcomes of 93 THA patients (20 men, 73 women; mean age 69.2 years). Patients were divided into three groups according to postoperative analgesic technique: CFNB, LIA, or combined CFNB+LIA. We measured the following postoperative outcome parameters: visual analog scale (VAS) for pain at rest, supplemental analgesia, side effects, mobilization, length of hospital stay, and Harris Hip Score (HHS). Results. The CFNB+LIA group had significantly lower VAS pain scores than the CFNB and LIA groups on postoperative day 1. There were no significant differences among the three groups in use of supplemental analgesia, side effects, mobilization, length of hospital stay, or HHS at 3 months after THA. Conclusions. Although there were no clinically significant differences in outcomes among the three groups, combination therapy with CFNB and LIA provided better pain relief after THA than CFNB or LIA alone, with few side effects.

Combination Therapy of Extrapyramidal Disease with Trihexyphenidyl and L-Dopa

1979 ◽  
Vol 7 (1) ◽  
pp. 19-28 ◽  
Author(s):  
H Hökendorf
Keyword(s):  
Side Effects ◽  
Combination Therapy ◽  
Motor System ◽  
Good Control ◽  
Decarboxylase Inhibitor ◽  
System Disease ◽  
Extrapyramidal Disease ◽  
Extrapyramidal Motor

An electromyographic method was used to study the effect of combination therapy with L-dopa and trihexyphenidyl on tremor in thirty patients suffering from extrapyramidal motor system disease. In this method tremor activity was measured and documented so that the course of the disease could be followed objectively. L-dopa alone was slightly more effective against tremor than was trihexyphenidyl alone. The combination of the two drugs was more effective than either drug used alone, and its side-effects were mild and definitely fewer than had been reported with L-dopa combined with a decarboxylase inhibitor. Good control of tremor with L-dopa and trihexyphenidyl was obtained clinically and verified electromyographically.

scholarly journals Opening the time window

2019 ◽  
Vol 39 (12) ◽  
pp. 2539-2540 ◽  
Author(s):  
Klaus van Leyen ◽  
Xiaoying Wang ◽  
Magdy Selim ◽  
Eng H Lo
Keyword(s):  
Side Effects ◽  
Combination Therapy ◽  
Patient Selection ◽  
Endovascular Therapy ◽  
Perfusion Imaging ◽  
Paradigm Shift ◽  
Time Window ◽  
Stroke Therapy ◽  
Image Guided ◽  
Tissue Plasminogen

The recently completed EXTEND trial tested the idea that tissue plasminogen activator thrombolysis can be safely extended up to 9 h after stroke onset if automated perfusion imaging indicates the presence of a salvageable penumbra. This important trial contributes to an ongoing paradigm shift for stroke therapy. Combined with the introduction of endovascular therapy, image-guided patient selection is expanding the toolbox of the stroke practitioner. At the same time, pushing the limits of reperfusion has raised important questions about mechanisms to pursue for combination therapy as well as potential approaches to mitigate side effects and optimize treatments for patients with various co-morbidities.

scholarly journals The Effect of Systemic Methotrexate and Cyclosporine Combination Therapy inPsoriasis Vulgaris Patients in Bandung, Indonesia

2021 ◽  
Vol 33 (3) ◽  
pp. 200
Author(s):  
Oki Suwarsa ◽  
Fatima Aulia Khairani ◽  
Syawalika Ulya Isneny ◽  
Erda Avriyanti ◽  
Hartati Purbo Dharmadji ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Side Effects ◽  
Adverse Effects ◽  
Combination Therapy ◽  
Combination Treatment ◽  
Psoriasis Vulgaris ◽  
Severity Index ◽  
Dermatology Clinic ◽  
Significant Difference ◽  
Pasi Score

Background: Methotrexate (MTX) and cyclosporine have been used as effective systemic mono-therapy for psoriasis. Several factors are considered to switch monotherapy to combination therapy because monotherapy is no longer effective and has higher side effects. Hence,clinicians have avoided systemic therapy combinations due to its toxicity. However, some studies showed that this combination therapy could be usedeffectively for psoriasis patients. Purpose: This study aimed to analyze the efficacy and adverse effects of systemic MTX and cyclosporine combination therapy in Indonesian psoriasis vulgaris patients. Methods: The retrospective study assessed the effectiveness of 3 monthsmono-therapyand combination therapy of systemic MTX and cyclosporine in psoriasisvulgaris patients from 2016–2017 in Dermatology Clinic, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia. Result: Psoriasis area and severity index (PASI) score 90 were achieved in the group MTX (50%) and cyclosporine group (50%), while none in the combination group.However, eight patients (50%) in group MTX and cyclosporine reached the primary endpoint of PASI 50. One patient in cyclosporine group had adverse effects on kidney profiles. Nonetheless, other patients had no biochemical changes. But, there was no significant difference in the change of PASI between each group (p=0.102). Conclusion: We propose that combination therapy of MTX and cyclosporine is relatively safe and efficacious in treating Indonesian psoriasis vulgaris patients. This combination treatment isas effective as MTX or cyclosporinemono-therapy.

Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat

2006 ◽  
Vol 291 (6) ◽  
pp. E1212-E1219 ◽  
Author(s):  
M. H. Vickers ◽  
P. L. Hofman ◽  
P. D. Gluckman ◽  
P. E. Lobie ◽  
W. S. Cutfield
Keyword(s):  
Growth Hormone ◽  
Side Effects ◽  
Combination Therapy ◽  
Gestational Age ◽  
Combination Treatment ◽  
Small For Gestational Age ◽  
Body Growth ◽  
Maternal Undernutrition ◽  
Fasting Plasma ◽  
Linear Body

Growth hormone (GH) therapy is often associated with adverse side effects, including impaired insulin sensitivity. GH treatment of children with idiopathic short stature does not lead to an optimized final adult height. It has been demonstrated that FFA reduction induced by pharmacological antilipolysis can stimulate GH secretion per se in both normal subjects and those with GH deficiency. However, to date, no investigation has been undertaken to establish efficacy of combination treatment with GH and FFA regulators on linear body growth. Using a model of maternal undernutrition in the rat to induce growth-restricted offspring, we investigated the hypothesis that combination treatment with GH and FFA regulators can enhance linear body growth above that of GH alone. At postnatal day 28, male offspring of normally nourished mothers (controls) and offspring born with low birth weight [small for gestational age (SGA)] were treated with saline, GH, or GH (5 mg·kg−1·day−1) in combination with acipimox (GH + acipimox, 20 mg·kg−1·day−1) or fenofibrate (GH + fenofibrate, 30 mg·kg−1·day−1) for 40 days. GH plus acipimox treatment significantly enhanced linear body growth in the control and SGA animals above that of GH, as quantified by tibial and total body length. Treatment with GH significantly increased fasting plasma insulin, insulin-to-glucose ratio, and plasma volumes in control and SGA animals but was not significantly different between saline and GH-plus-acipimox-treated animals. GH-induced lipolysis was blocked by GH plus acipimox treatment in both control and SGA animals, concomitant with a significant reduction in fasting plasma FFA and insulin concentrations. This is the first study to show that GH plus acipimox combination therapy, via pharmacological blocking of lipolysis during GH exposure, can significantly enhance the efficacy of GH in linear growth promotion and ameliorate unwanted metabolic side effects.

Sign in / Sign up

Export Citation Format

Share Document